untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:33:13Z</responseDate>
<request identifier=oai:HAL:hal-00875092v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-00875092v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-PARIS5</setSpec>
<setSpec>collection:UNIV-PARIS7</setSpec>
<setSpec>collection:UPMC</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:HL</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.</title>
<creator>Assoumou, Lambert</creator>
<creator>Descamps, Diane</creator>
<creator>Yerly, Sabine</creator>
<creator>Dos Santos, Georges</creator>
<creator>Marcelin, Anne-Geneviève</creator>
<creator>Delaugerre, Constance</creator>
<creator>Morand-Joubert, Laurence</creator>
<creator>Ruffault, Annick</creator>
<creator>Izopet, Jacques</creator>
<creator>Plantier, Jean-Christophe</creator>
<creator>Pakianather, Sophie</creator>
<creator>Montes, Brigitte</creator>
<creator>Chaix, Marie-Laure</creator>
<creator>Wirden, Marc</creator>
<creator>Costagliola, Dominique</creator>
<creator>Masquelier, Bernard</creator>
<creator>Michelet, Christian</creator>
<contributor>Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH ; Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Laboratoire de Virologie ; Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Bichat - Claude Bernard [Paris]</contributor>
<contributor>Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales ; Université Paris Diderot - Paris 7 (UPD7) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Service de bactériologie-virologie ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Saint-Antoine [APHP]</contributor>
<contributor>Unité de Rétrovirologie ; Hôpital Pontchaillou</contributor>
<contributor>Laboratoire de Virologie [Purpan] ; CHU Toulouse [Toulouse] - Hôpital Purpan - Institut Fédératif de Biologie (IFB)</contributor>
<contributor>Unité de virologie générale ; Hôpital Charles Nicolle - CHU Rouen - Département de microbiologie : Bactério, Virologie, Parasito, Hygiène</contributor>
<contributor>Infections à Vih, Réservoirs, Pharmacologie des Antirétroviraux et Prévention de la Transmission Mère Enfant ; Université Paris Descartes - Paris 5 (UPD5)</contributor>
<contributor>Service de virologie et d'immunologie biologique ; CHU Bordeaux [Bordeaux] - Groupe hospitalier Pellegrin</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<description>International audience</description>
<source>ISSN: 0305-7453</source>
<source>EISSN: 1460-2091</source>
<source>Journal of Antimicrobial Chemotherapy</source>
<publisher>Oxford University Press (OUP)</publisher>
<identifier>hal-00875092</identifier>
<identifier>https://hal.archives-ouvertes.fr/hal-00875092</identifier>
<source>https://hal.archives-ouvertes.fr/hal-00875092</source>
<source>Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2013, 68 (6), pp.1400-5. 〈10.1093/jac/dkt033〉</source>
<identifier>DOI : 10.1093/jac/dkt033</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dkt033</relation>
<identifier>PUBMED : 23404192</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/23404192</relation>
<language>en</language>
<subject lang=en>antiretroviral therapy</subject>
<subject lang=en>epidemiology</subject>
<subject lang=en>HIV-1 drug resistance</subject>
<subject lang=en>multidrug resistance</subject>
<subject lang=en>plasma HIV RNA</subject>
<subject lang=en>virological failure</subject>
<subject>[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>BACKGROUND: Surveillance of HIV-1 drug resistance in treated patients with plasma viral load (VL) >50 copies/mL. METHODS: The protease and reverse transcriptase (RT) genes were systematically sequenced in samples from 756 patients with VL >50 copies/mL in 2009. The genotyping results were interpreted for each antiretroviral drug (ARV) by using the ANRS algorithm v21. Weighted analyses were used to derive representative estimates of percentages of patients. Prevalence rates were compared with those obtained in 2004 among patients with VL >1000 copies/mL. RESULTS: Sequences were obtained for 506 patients. Sequencing was successful in 45%, 80% and 96% of samples with VL of 51-500, 501-1000 and >1000 copies/mL, respectively. Resistance or possible resistance to at least one ARV was observed in 59% of samples. Overall, 0.9% of samples contained viruses resistant to all drugs belonging to at least three drug classes. All resistance prevalence rates were significantly lower in 2009 than in 2004. CONCLUSION: In France, where 86% of patients were receiving combination antiretroviral therapy in 2009, only 15.0% of patients had a VL >50 copies/mL, suggesting that only 8.9% of treated patients could potentially transmit resistant viruses. Only 0.08% of patients harboured viruses fully resistant to at least three antiretroviral drug classes. Further studies are needed to determine whether resistance continues to decline over time.</description>
<contributor>ANRS AC11 Resistance Group</contributor>
<date>2013-06</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
